Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does DOBUTAMINE Cause Benign prostatic hyperplasia? 24 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 24 reports of Benign prostatic hyperplasia have been filed in association with DOBUTAMINE (Dobutamine). This represents 1.5% of all adverse event reports for DOBUTAMINE.

24
Reports of Benign prostatic hyperplasia with DOBUTAMINE
1.5%
of all DOBUTAMINE reports
24
Deaths
23
Hospitalizations

How Dangerous Is Benign prostatic hyperplasia From DOBUTAMINE?

Of the 24 reports, 24 (100.0%) resulted in death, 23 (95.8%) required hospitalization, and 23 (95.8%) were considered life-threatening.

Is Benign prostatic hyperplasia Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for DOBUTAMINE. However, 24 reports have been filed with the FAERS database.

What Other Side Effects Does DOBUTAMINE Cause?

Drug ineffective (556) Off label use (325) Cardiogenic shock (316) Multiple organ dysfunction syndrome (297) Condition aggravated (272) Sepsis (264) Abdominal distension (259) General physical health deterioration (258) Hyponatraemia (256) Appendicitis (252)

What Other Drugs Cause Benign prostatic hyperplasia?

TADALAFIL (596) TAMSULOSIN (304) FINASTERIDE (266) PANTOPRAZOLE (261) PREDNISONE (257) ALBUTEROL (254) ASPIRIN (243) TIOTROPIUM (235) RAMIPRIL (193) AMLODIPINE (179)

Which DOBUTAMINE Alternatives Have Lower Benign prostatic hyperplasia Risk?

DOBUTAMINE vs DOBUTAMINE\DOBUTAMINE DOBUTAMINE vs DOCETAXEL DOBUTAMINE vs DOCETAXEL ANHYDROUS DOBUTAMINE vs DOCETAXEL\DOCETAXEL ANHYDROUS DOBUTAMINE vs DOCONEXENT

Related Pages

DOBUTAMINE Full Profile All Benign prostatic hyperplasia Reports All Drugs Causing Benign prostatic hyperplasia DOBUTAMINE Demographics